LONG-TERM URSODEOXYCHOLIC ACID THERAPY REDUCES ANTI-CYTOKERATIN SUBCLASS ANTIBODY-FORMATION RELATED TO BILE-DUCT DESTRUCTION IN PRIMARY BILIARY-CIRRHOSIS

被引：0
|
作者：
ODA, M [1 ]
KANEKO, H [1 ]
KAZEMOTO, S [1 ]
ISHII, K [1 ]
YOKOMORI, H [1 ]
AZUMA, T [1 ]
NAKAMURA, M [1 ]
TSUCHIYA, M [1 ]
机构：
[1] KEIO UNIV,SCH MED,DEPT INTERNAL MED,TOKYO 108,JAPAN
来源：
GASTROENTEROLOGY | 1993年 / 104卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A966 / A966
页数：1
相关论文
共 22 条
  • [11] Long-term ursodeoxycholic acid therapy delays histologic progression in primary biliary cirrhosis.
    Angulo, P
    Batts, KP
    Therneau, TM
    Jorgensen, RA
    Dickson, ER
    Lindor, KD
    GASTROENTEROLOGY, 1998, 114 (04) : A1203 - A1203
  • [12] Disappearance of antimitochondrial antibody in primary biliary cirrhosis during long-term ursodeoxycholic acid treatment.
    Yamazaki, K
    Nakamura, A
    Abe, S
    Abe, K
    Suzuki, K
    Sato, S
    GASTROENTEROLOGY, 1996, 110 (04) : A1364 - A1364
  • [13] Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years
    Chan, CW
    Gunsar, F
    Feudjo, M
    Rigamonti, C
    Vlachogiannakos, J
    Carpenter, JR
    Burroughs, AK
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (03) : 217 - 226
  • [14] LONG-TERM EFFECT OF URSODEOXYCHOLIC ACID (UDCA) ON HEPATIC-FUNCTION AND PORTAL-HYPERTENSION IN PRIMARY BILIARY-CIRRHOSIS (PBC)
    HUET, PM
    HUET, J
    HOTTE, S
    HEPATOLOGY, 1994, 20 (04) : A202 - A202
  • [15] EFFECT OF LONG-TERM TREATMENT WITH URSODIOL ON CLINICAL AND BIOCHEMICAL FEATURES AND BILIARY BILE-ACID METABOLISM IN PATIENTS WITH PRIMARY BILIARY-CIRRHOSIS
    BATTA, AK
    SALEN, G
    MIRCHANDANI, R
    TINT, GS
    SHEFER, S
    BATTA, M
    ABROON, J
    OBRIEN, CB
    SENIOR, JR
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1993, 88 (05): : 691 - 700
  • [16] LONG-TERM THERAPY WITH BEZAFIBRATE AND URSODEOXYCHOLIC ACID IS INSUFFICIENT FOR PREVENTING DISEASE PROGRESSION IN PATIENTS WITH ADVANCED PRIMARY BILIARY CIRRHOSIS
    Reig, A.
    Sese, P.
    Pares, A.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S806 - S806
  • [17] Anti-GP210 antibody titer as a clinical parameter that predicts the long-term outcome of primary biliary cirrhosis under ursodeoxycholic acid treatment.
    Nakamura, M
    Shimizu-Yoshida, Y
    Takii, Y
    Komori, A
    Yokoyama, T
    Ueki, T
    Daikoku, M
    Yano, K
    Matsumoto, T
    Yatsuhashi, H
    Ito, M
    Ishibashi, H
    HEPATOLOGY, 2004, 40 (04) : 458A - 459A
  • [18] The impact of ursodeoxycholic acid (UDCA) therapy with or without liver transplantation (OLT) on long-term survival in primary biliary cirrhosis.
    Corpechot, C
    Carrat, F
    Bahr, A
    Poupon, RE
    Poupon, R
    HEPATOLOGY, 2003, 38 (04) : 519A - 519A
  • [19] A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia
    Hosonuma, Kenichi
    Sato, Ken
    Yamazaki, Yuichi
    Yanagisawa, Masatoshi
    Hashizume, Hiroaki
    Horiguchi, Norio
    Kakizaki, Satoru
    Kusano, Motoyasu
    Yamada, Masanobu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (03): : 423 - 431
  • [20] URSODEOXYCHOLIC ACID IN THE TREATMENT OF PRIMARY BILIARY-CIRRHOSIS - A SHORT-TERM, RANDOMIZED, DOUBLE-BLIND CONTROLLED, CROSS-OVER STUDY WITH LONG-TERM FOLLOW-UP
    HWANG, SJ
    CHAN, CY
    LEE, SD
    WU, JC
    TSAY, SH
    LO, KJ
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1993, 8 (03) : 217 - 223
123